MerusMRUS
MRUS
About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Employees: 260
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
313% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $4.13M
31% more funds holding in top 10
Funds holding in top 10: 13 [Q4 2024] → 17 (+4) [Q1 2025]
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
1% more capital invested
Capital invested by funds: $2.96B [Q4 2024] → $2.98B (+$23.5M) [Q1 2025]
0.27% less ownership
Funds ownership: 102.79% [Q4 2024] → 102.53% (-0.27%) [Q1 2025]
4% less funds holding
Funds holding: 192 [Q4 2024] → 185 (-7) [Q1 2025]
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$88
61%
upside
Avg. target
$99
81%
upside
High target
$110
101%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
BMO Capital Evan David Seigerman | 101%upside $110 | Outperform Maintained | 23 May 2025 |
Needham Ami Fadia | 61%upside $88 | Buy Maintained | 23 May 2025 |
Wells Fargo Eva Fortea Verdejo | 63%upside $89 | Overweight Maintained | 8 May 2025 |
Guggenheim Michael Schmidt | 100%upside $109 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 7 articles about MRUS published over the past 30 days
Positive
Seeking Alpha
3 days ago
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rates could drive long-term value if validated in future studies.
Positive
CNBC Television
1 week ago
Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer
CNBC's Angelica Peebles sits down with Merus CEO Dr. Bill Lundberg to discuss the company's recent positive results in head & neck cancer and what he sees for the future of bispecific antibody drugs
Neutral
GlobeNewsWire
1 week ago
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus.
Neutral
GlobeNewsWire
1 week ago
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 weeks ago
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Positive
Investors Business Daily
3 weeks ago
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.
Neutral
GlobeNewsWire
3 weeks ago
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
1 month ago
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
1 month ago
Merus to Present at BofA Securities 2025 Health Care Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Negative
Zacks Investment Research
1 month ago
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Charts implemented using Lightweight Charts™